Rate My Professor Andrew Sewell

Sewell’s research focuses on T-cell antigens and the receptors that recognize them, spanning infection, transplant tolerance, vaccination, cancer immunotherapy, and autoimmune disease. His group has pioneered discoveries such as novel anticancer T-cells with broad tumor specificity, including MR1-restricted T-cells that target diverse cancers independently of traditional MHC presentation, raising prospects for universal therapies. Notable publications include "Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy" (Cell, 2023), demonstrating how single T-cell receptors engage multiple cancer antigens in patients with complete remission; "Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope" (Cell, 2022), identifying viral mutation strategies; "Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1" (Nature Immunology, 2020), revealing pan-cancer T-cell potential; and "A probiotic bacterium modulates antitumour γδ T-cell responses in lung cancer" (Frontiers in Immunology, 2026). With over 17,000 citations across 338 publications, Sewell’s contributions have profoundly influenced immunotherapy development, fostering international collaborations and clinical advancements.